2. Search Result
Search Result
Results for "

tumor inhibition

" in MedChemExpress (MCE) Product Catalog:

165

Inhibitors & Agonists

1

Screening Libraries

1

Biochemical Assay Reagents

2

Peptides

6

Inhibitory Antibodies

17

Natural
Products

1

Recombinant Proteins

6

Isotope-Labeled Compounds

2

Antibodies

4

Click Chemistry

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16496
    Thiarabine

    OSI-7836

    		 DNA/RNA Synthesis Inflammation/Immunology Cancer
    Thiarabine (OSI-7836) shows potent anti-tumor activity and inhibition of DNA synthesis.
    Thiarabine
  • HY-153364
    FTX-6746

    		PPAR Cancer
    FTX-6746 is an orally active PPARG inhibitor. FTX-6746 shows potent tumor inhibition in mouse xenograft models .
    FTX-6746
  • HY-141896
    RET-IN-7

    		RET Cancer
    RET-IN-7 demonstrates potent in vitro RET kinase inhibition and robust in vivo efficacy in RET-driven tumor xenografts upon multiday dosing in mice.
    RET-IN-7
  • HY-162881
    DS06652923

    		EGFR Cancer
    DS06652923 is an orally active EGFR triple mutation inhibitor. DS06652923 has a growth inhibition effect on Ba/F3 EGFR del19/T90M/C797S cells, with a GI50 value of 9.4 nM. DS06652923 can lead to tumor regression in Ba/F3 xenograft models .
    DS06652923
  • HY-18652A
    Avutometinib potassium

    Ro 5126766 potassium; CH5126766 potassium

    		 Raf MEK Cancer
    Avutometinib (CH5126766) (potassium) is a RAF/MEK clamp that potently inhibits RAF/MEK kinase activity and induces dominant negative RAF-MEK complexes preventing phosphorylation of MEK by ARAF, BRAF and CRAF. Avutometinib (potassium) shows anti-proliferative potency across tumor cell lines carrying KRAS mutations including PDAC cell lines. Avutometinib (potassium) induces tumor inhibition and increases survival in a KRAS/p53 pancreatic cancer mouse model. Avutometinib (potassium) is promising for research of low-grade-serous-ovarian-carcinoma (LGSOC), ovarian cancer and pancreatic ductal adenocarcinoma (PDAC) .
    Avutometinib potassium
  • HY-156350
    SGC-STK17B-1

    		Others Cancer
    SGC-STK17B-1 is an ATP-competitive and selective STK17B inhibitor (IC50: 34 nM, KD: 5.6 nM) .
    SGC-STK17B-1
  • HY-121470
    Vesamicol

    		Others Others
    Vesamicol is a compound used to synthesize radiolabeled derivatives that can be used as sigma receptor ligands for tumor targeting inhibition and have shown certain potential in cellular uptake, biodistribution and inhibition experiments.
    Vesamicol
  • HY-115908
    ZDLD13

    		CDK Apoptosis Cancer
    ZDLD13, a β-carboline, is an orally active and selective CDK4/CycD3 inhibitor with an IC50 value of 0.38 μM. ZDLD13 exhibits potent anti-HCT116 activity including inhibition of colony formation, inhibition of invasion and migration, inducing of apoptosis, and arresting of G1 phase in cell cycle. ZDLD13 shows significant tumor growth inhibition in HCT116 tumor xenograft model .
    ZDLD13
  • HY-120187
    DDCPPB-Glu

    		Others Others
    DDCPPB-Glu (compound 3a) is a compound with anti-tumor activity, which has the activity of inhibiting tumor cell growth and prolonging survival. DDCPPB-Glu has growth inhibition effect on various tumor cell lines, can increase the survival time of leukemia mice, and has inhibitory effect on tumors such as colon cancer and lung cancer.
    DDCPPB-Glu
  • HY-119618
    R1498

    		Others Cancer
    R1498 is a multi-target kinase inhibitor with anti-angiogenic and anti-proliferative activities. R1498 mainly targets targets such as Aurora kinase and VEGFR2, which are associated with tumor development. R1498 showed moderate in vitro growth inhibition in a variety of tumor cells, with IC50 values in the micromolar range. R1498 showed anti-tumor efficacy superior to sorafenib in a variety of gastric cancer and hepatocellular carcinoma xenograft models, with tumor growth inhibition rates exceeding 80%, and tumor shrinkage was observed in some models. R1498 showed a 10-30% tumor shrinkage rate in three xenograft models derived from human primary gastric cancer tumors, further demonstrating its inhibitory potential. R1498 effectively inhibited Aurora A activity in vivo and reduced tumor vascularization .
    R1498
  • HY-156566
    PROTAC BRD4 Degrader-21

    		Epigenetic Reader Domain PROTACs Cancer
    PROTAC BRD4 Degrader-21 (Comp 74) is a PROTAC degrader of BRD4. PROTAC BRD4 Degrader-21 displays significant tumor growth inhibition in tumor -bearing xenograft models in mice and can be used for anticancer research .
    PROTAC BRD4 Degrader-21
  • HY-144125
    Antitumor agent-41

    		Apoptosis Cancer
    Antitumor agent-41 (compound N-12), a potent antitumor agent, enhibits excellent antimigration and anti-invasion activity. Antitumor agent-41 (compound N-12) induces tumor inhibition via tumor necrosis and inflammatory response .
    Antitumor agent-41
  • HY-14754
    Salirasib
    5+ Cited Publications

    S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS

    		 Ras Autophagy Cancer
    Salirasib is a Ras inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.
    Salirasib
  • HY-157029S
    KRASG12D-IN-1

    		Ras Cancer
    KRASG12D-IN-1 (compound 22) is a KRAS G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .
    KRASG12D-IN-1
  • HY-157031S
    KRASG12D-IN-2

    		Ras Cancer
    KRASG12D-IN-2 (compound 28) is a KRAS G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .
    KRASG12D-IN-2
  • HY-147664
    hCAXII-IN-1

    		Carbonic Anhydrase Cancer
    These compounds show selective inhibition on tumor related subtypes HCA IX and XII, and are also considered as the leading molecules for the development of future cancer therapeutic drugs based on new mechanisms of action.
    hCAXII-IN-1
  • HY-168011
    GPX4-IN-14

    		Ferroptosis Glutathione Peroxidase Reactive Oxygen Species Cancer
    GPX4-IN-14 (compound 2c) is an inhibitor of GPX4, with free radical scavenging activity (maximum scavenging rate is 72.52%) and anti-tumor proliferation activity in vitro. GPX4-IN-14 inhibits GPX4 protein, increases lipid peroxide levels and intracellular Reactive Oxygen Species (ROS) levels, thereby inducing ferroptosis and exerting anti-tumor proliferation effects .
    GPX4-IN-14
  • HY-B0021
    Doxifluridine
    2 Publications Verification

    Ro 21-9738; 5-Fluoro-5'-deoxyuridine; 5'-DFUR

    		 Thymidylate Synthase Cancer
    Doxifluridine has anticancer activity. Doxifluidine is a 5-FU prodrug. Doxifluridine is a thymidine synthase inhibitor. Doxifluridine can enhance tumor inhibition by synergizing with a variety of drugs .
    Doxifluridine
  • HY-156568A
    SMD-3040 TFA

    		PROTACs Epigenetic Reader Domain Cancer
    SMD-3040 TFA is a selective degrader of SMARCA2. SMD-3040 TFA contains SMARCA2/4 ligands, linker and VHL ligands and can be used for PROTAC drug synthesis. SMD-3040 TFA exhibits strong tumor growth inhibition in tumor xenograft models .
    SMD-3040 TFA
  • HY-135818
    XM462

    		Others Cancer
    XM462 is a dihydroceramide desaturase inhibitor. XM462 produced a mixed-type inhibition (Ki=2 μM) in vitro. XM462 has dihydroceramide desaturase inhibition both in vitro and in cultured cells with IC50 values of 8.2 and 0.78 μM, respectively. XM462 can be used for the research of tumor .
    XM462
  • HY-13603
    Crolibulin
    1 Publications Verification

    EPC2407

    		 Microtubule/Tubulin Apoptosis Cancer
    Crolibulin (EPC2407) is a tubulin polymerization inhibitor, with potent apoptosis induction and cell growth inhibition. Crolibulin has anti-tumor activity. Crolibulin also has cardiovascular toxicity and neurotoxicity .
    Crolibulin
  • HY-114228
    PROTAC BET degrader-2
    1 Publications Verification

    		 PROTACs Epigenetic Reader Domain Cancer
    PROTAC BET degrader-2 is a PROTAC connected by ligands for Cereblon and BET with an IC50 value of 9.6 nM in cell growth inhibition in the RS4;11 cells and capable of achieving tumor regression.
    PROTAC BET degrader-2
  • HY-N2357
    Eudesmin

    (-)-Eudesmin; Eudesmine; (-)-Eudesmine

    		 Ribosomal S6 Kinase (RSK) Infection Metabolic Disease Inflammation/Immunology Cancer
    Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities .
    Eudesmin
  • HY-168147
    Enpp-1-IN-24

    		Phosphodiesterase (PDE) Cancer
    Enpp-1-IN-24 (compund 7) is an ENPP1 inhibitor that, in combination with anti-PD-1 antibodies, achieves 77.7% tumor growth inhibition and improves survival in mouse models .
    Enpp-1-IN-24
  • HY-154362A
    β-D-Ribofuranose, 3-deoxy-3-fluoro-, 1,2-diacetate 5-4-methylbenzoate

    		Others Cancer
    β-D-Ribofuranose, 3-deoxy-3-fluoro-, 1,2-diacetate 5-(4-methylbenzoate) (compound 25) displays potent tumor cell growth inhibition activity .
    β-D-Ribofuranose, 3-deoxy-3-fluoro-, 1,2-diacetate 5-4-methylbenzoate
  • HY-116506
    Bigelovin

    		RAR/RXR Reactive Oxygen Species Apoptosis Autophagy Cancer
    Bigelovin, a sesquiterpene lactone isolated from Inula hupehensis, is a selective retinoid X receptor α agonist. Bigelovin suppresses tumor growth through inducing apoptosis and autophagy via the inhibition of mTOR pathway regulated by ROS generation .
    Bigelovin
  • HY-13540
    E7016

    GPI 21016

    		 PARP Cancer
    E7016 (GPI 21016) is an orally available PARP inhibitor. E7016 can enhance tumor cell radiosensitivity in vitro and in vivo through the inhibition of DNA repair. E7016 acts as a potential anticancer agent .
    E7016
  • HY-122315
    Oncrasin-60

    NSC-741909

    		 Others Others
    Oncrasin-60 (NSC-741909) is a compound with antitumor activity that is active against multiple cancer cell lines in vitro and can induce tumor regression in vivo, with its mechanism involving JNK activation and STAT3 inhibition.
    Oncrasin-60
  • HY-137831
    TLBC

    		Apoptosis Cancer
    TLBC, a boronic-chalcone derivative, shows a dose-dependent inhibition with IC50 values of 5.5-25.5 μM in various glioma cell lines. TLBC induces apoptosis independent of changes to the tumor suppressor p53 .
    TLBC
  • HY-400685
    SMD-3040 intermediate-2

    		Others Cancer
    SMD-3040 intermediate-2 is an intermediate in the synthesis of SMD-3040 (HY-156568). SMD-3040 contains SMARCA2/4 ligands, linker and VHL ligands and is a selective SMARCA2 degrader. MD-3040 can be used for ADC drug synthesis and has strong tumor growth inhibition in tumor xenograft models .
    SMD-3040 intermediate-2
  • HY-141677B
    INCB059872 tosylate

    		Histone Demethylase Cancer
    INCB059872 tosylate is a potent, selective and orally active lysine-specific demethylase 1 inhibitor. INCB059872 binds to and inhibits LSD1, enhancing H3K4 methylation, thereby increasing the expression of tumor suppressor genes. INCB059872 inhibition also promotes H3K9 methylation, thereby reducing the transcription of tumor-promoting genes .
    INCB059872 tosylate
  • HY-134904
    RMC-6272
    1 Publications Verification

    RM-006

    		 mTOR Cancer
    RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors .
    RMC-6272
  • HY-N2995
    Poricoic acid A

    Poricoic acid A(F)

    		 NF-κB Keap1-Nrf2 Cancer
    Poricoic acid A, isolated from Poria cocos, possesses anti-tumor activity . Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis .
    Poricoic acid A
  • HY-145406
    IHCH-3064

    		Adenosine Receptor HDAC Inflammation/Immunology Cancer
    IHCH-3064 is a dual-acting compounds targeting Adenosine A2A Receptor and HDAC. IHCH-3064 exhibits potent binding to A2AR (Ki=2.2 nM) and selective inhibition of HDAC1 (IC50=80.2 nM), with good antiproliferative activity against tumor cell lines in vitro. IHCH-3064 is a tumor immunotherapeutic agent.
    IHCH-3064
  • HY-155376
    mTOR inhibitor-14

    		mTOR Cancer
    mTOR inhibitor-14 (compound 14c) is a potent mTOR inhibitor. mTOR inhibitor-14 also shows minimal CYP2C8 inhibition. mTOR inhibitor-14 can inhibit tumor growth .
    mTOR inhibitor-14
  • HY-163548
    SPP-002

    		Sialyltransferase Cancer
    SPP-002 is a sulfate analogue that acts as a potential Sialyltransferase (ST) inhibitor. SPP-002 selectively inhibits n-glycosialylation with inhibition at least an order of magnitude greater than that of unmodified parental cholic acid (LCA). SPP-002 reduces tumor cell migration and invasion by inhibiting the integrin /FAK/Paxillin signaling pathway. SPP-002 can be used in the study of tumor metastasis .
    SPP-002
  • HY-109139A
    Taminadenant mesylate

    NIR178 mesylate; PBF509 mesylate

    		 Adenosine Receptor Cancer
    Taminadenant mesylate (NIR178 mesylate) is a potent adenosine A2A receptor antagonist with potential anti-tumor activity. Taminadenant mesylate can selectively bind and inhibit A2AR on T lymphocytes, thereby releasing adenosine/A2AR-mediated inhibition of T lymphocytes and activating T cell-mediated immune responses against tumor cells. Taminadenant mesylate works by reducing the proliferation of susceptible tumor cells. Taminadenant mesylate also showed effectiveness in reversing dyskinesias in Parkinson's disease models and was able to inhibit dyskinesias caused by L-DOPA .
    Taminadenant mesylate
  • HY-101571A
    PF-06821497

    		Epigenetic Reader Domain Histone Methyltransferase Cancer
    PF-06821497 (compound 23a) is a potent, selective and orally active Enhancer of Zeste Homolog 2 (EZH2) inhibitor, with a Ki value <0.1 nM against mutant Y641N EZH2. Exhibits robust tumor growth inhibition .
    PF-06821497
  • HY-114585
    Sperabillin A

    		Bacterial Infection Cancer
    Sperabillin A is an antibacterial agent against gram-positive and gram-negative bacteria. Sperabillin A shows strong inhibition of human umbilical vein endothelial (HUVE) cell proliferation. Sperabillin A also shows anti-tumor acfivity against B16 melanoma in mouse .
    Sperabillin A
  • HY-14375
    CB 300919

    		NAMPT Cancer
    CB 300919 is a quinazoline-based antitumour agent with high activity in the CH1 human ovarian tumour xenograft. CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft .
    CB 300919
  • HY-161419
    EZH2-IN-18

    		Histone Methyltransferase Cancer
    EZH2-IN-18 (compound 9e) is a potent inhibitor of enhancer of zeste homologue 2 (EZH2 WT) , with the IC50 of 1.01 nM. EZH2-IN-18 shows inhibition in proliferation and induction in apoptosis in tumor cells .
    EZH2-IN-18
  • HY-13016A
    Cabozantinib hydrochloride

    XL184 hydrochloride; BMS-907351 hydrochloride

    		 VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis Cancer
    Cabozantinib hydrochloride is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035 and 1.3 nM, respectively. Cabozantinib hydrochloride displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib hydrochloride shows antiangiogenic activity. Cabozantinib hydrochloride disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .
    Cabozantinib hydrochloride
  • HY-32015
    Cot inhibitor-1
    2 Publications Verification

    		 MAP3K Inflammation/Immunology
    Cot inhibitor-1 (compound 28) is a selective tumor progression loci-2 (Tpl2) kinase inhibitor with an IC50 of 28 nM. Cot inhibitor-1 shows an inhibition of TNF-alpha production in human whole blood with an IC50 of 5.7 nM .
    Cot inhibitor-1
  • HY-10619B
    Niraparib tosylate
    55+ Cited Publications

    MK-4827 tosylate

    		 PARP Apoptosis Cancer
    Niraparib tosylate (MK-4827 tosylate) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with an IC50 of 3.8 and 2.1 nM, respectively. Niraparib tosylate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity .
    Niraparib tosylate
  • HY-P99192
    Emibetuzumab

    LY2875358

    		 c-Met/HGFR Cancer
    Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .
    Emibetuzumab
  • HY-B0021R
    Doxifluridine (Standard)

    Ro 21-9738 (Standard); 5-Fluoro-5'-deoxyuridine (Standard); 5'-DFUR (Standard)

    		 Thymidylate Synthase Cancer
    Doxifluridine (Standard) is the analytical standard of Doxifluridine. This product is intended for research and analytical applications. Doxifluridine has anticancer activity. Doxifluidine is a 5-FU prodrug. Doxifluridine is a thymidine synthase inhibitor. Doxifluridine can enhance tumor inhibition by synergizing with a variety of drugs .
    Doxifluridine (Standard)
  • HY-161515
    BRD4/NAMPT-IN-1

    		NAMPT Epigenetic Reader Domain Cancer
    BRD4/NAMPT-IN-1 (Compound A2) shows strong inhibitory effects on NAMPT and BRD4 (IC50=35 nM (NAMPT) and 58 nM (BRD4)). BRD4/NAMPT-IN-1 inhibits the growth and migration of hepatocellular carcinoma cells and promotes apoptosis. BRD4/NAMPT-IN-1 also shows potent anticancer effects in HCCLM3 xenograft mouse model, with no obvious toxic effects .
    BRD4/NAMPT-IN-1
  • HY-13016
    Cabozantinib
    35+ Cited Publications

    XL184; BMS-907351

    		 VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis Cancer
    Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .
    Cabozantinib
  • HY-100653
    AZD5153
    1 Publications Verification

    		 Others Cancer
    AZD5153 (Compound 13) is a trivalent triazolpyrazine bromide domain (BRD), bromodomain and extraterminal (BET) inhibitor. AZD5153 has down-regulated c-Myc gene and tumor growth inhibition activity. AZD5153 can be used in the study of BET small molecule inhibitors .
    AZD5153
  • HY-B0021S1
    Doxifluridine-d3

    Ro 21-9738-d3; 5-Fluoro-5'-deoxyuridine-d3; 5'-DFUR-d3

    		 Thymidylate Synthase Isotope-Labeled Compounds Cancer
    Doxifluridine-d3 is deuterated labeled Doxifluridine (HY-B0021). Doxifluridine has anticancer activity. Doxifluidine is a 5-FU prodrug. Doxifluridine is a thymidine synthase inhibitor. Doxifluridine can enhance tumor inhibition by synergizing with a variety of drugs .
    Doxifluridine-d3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: